循环肿瘤细胞：前列腺癌治疗评估的可靠生物标志物？

Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?

作者信息

Ciccarese Chiara, Montironi Rodolfo, Fiorentino Michelangelo, Martignoni Guido, Brunelli Matteo, Iacovelli Roberto, Lopez-Beltran Antonio, Cheng Liang, Scarpelli Marina, Moch Holger, Tortora Giampaolo, Massari Francesco

机构信息

Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona. Italy.

Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, AOU Ospedali Riuniti, Ancona. Italy.

出版信息

Curr Drug Metab. 2017;18(8):692-699. doi: 10.2174/1389200218666170518163549.

DOI:10.2174/1389200218666170518163549

PMID:28524006

Abstract

BACKGROUND

Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide spectrum of clinical behavior. To date, several treatment options are available, whose selection is currently based mainly on clinical criteria. Given the weakness of conventional imaging and PSA assay, the identification of a prognostic and predictive biomarker for choosing the appropriate treatment and monitoring its efficacy is a very topical issue in prostate cancer management. Circulating tumor cells (CTCs) have substantial promise for early tumor diagnosis, disease recurrence and metastatic spread monitoring as well as for biological tumor characterization, thus representing a reliable translational real-time biomarkers of prostate cancer.

CONCLUSION

This paper summarized the main data available about CTCs detection, their prognostic value, and their potential predictive role for metastatic prostate cancer patients management.

摘要

背景

前列腺癌是一种常见的恶性肿瘤，具有高度的分子异质性，导致广泛的临床行为。迄今为止，有几种治疗选择，目前其选择主要基于临床标准。鉴于传统成像和PSA检测的局限性，识别一种用于选择合适治疗方法并监测其疗效的预后和预测生物标志物是前列腺癌管理中一个非常热门的问题。循环肿瘤细胞（CTC）在早期肿瘤诊断、疾病复发和转移扩散监测以及肿瘤生物学特征分析方面具有巨大潜力，因此是前列腺癌可靠的转化实时生物标志物。